378 - Response to neoadjuvant therapy and disease free survival and overall survival in patients with triple-negative breast cancer (TNBC): single center...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer agents
Breast Cancer
Biological Therapy
Presenter Tomas Pascual
Authors T. Pascual1, E. Ciruelos2, L. Manso2, I. Ghanem2, R.A. Manneh2, C. Mendiola2, D. Lora3, H. Cortes-Funes1
  • 1Servicio De Oncologia Medica, Hopital 12 de Octubre, 28005 - Madrid/ES
  • 2Medical Oncology, Hopital 12 de Octubre, 28005 - Madrid/ES
  • 3Clinical Investigation Unit, Imas12, University Hospital 12 de Octubre, Madrid/ES



Triple negative breast cancer (TNBC) is a distinct subtype of BC wich is characterized by the absence of expression of estrogen receptor (ER), progesterone receptor (PR) or HER2/neu. TNBC is a very heterogeneous disease, that accounts for 15 to 20% of breast cancers. Despite initial chemosensitivity, patients with TNBC had a poorer outcome in terms of disease-free and overall survival, compared to non-triple-negative breast cancers. Neoadjuvant chemotherapy is commonly used for the initial treatment for TNBC, allowing for a higher rate of breast-conserving surgery and giving clues about the individual responsiveness of a particular cancer to chemotherapy.


We retrospectively reviewed 66 TNBC patients treated with neoadjuvant chemotherapy diagnosed at our institution between 2001-2011. They were divided into three subgroups: complete pathological response after neoadjuvant chemotherapy (group A), residual tumor smaller than 1 centimeter wide (group B), and residual tumor bigger than 1 centimeter wide or involving lymph nodes.


(One patient died before surgery and another patient refused it. Twenty (31%) of the other 64 patients achieved a complete pathological response. Mean DFS was 2,15 years; recurrent disease was higher for C (20,64%) vs B (3pts, 23%) vs A (2 pts, 10%) (p = 0,0003). Most common recurrent sites were local (18) and bone (9). Mean OS was 4,5 years (95% IC 3,6 – 5,4); 3 (15%) pts died in A, 3 (23%) in B vs 16 (51%) in C (p = 0,03).


The pathologic complete response rate seen in our series is consistent with the one reported in other studies involving neoadjuvant chemotherapy for TNBC. The pathologic response after a neoadjuvant therapy correlates with disease-free and overall survival rates.


All authors have declared no conflicts of interest.